Upload
others
View
2
Download
0
Embed Size (px)
Citation preview
Public-Private Partnerships in Life Sciences – Co-creation, Co-innovation and
how to get Started?
27.9.2019Outi Tuovila
Agenda
9.00 Opening
Outi Tuovila, Senior Advisor, Business Finland
9.05 Business Finland research funding
Pekka Ollikainen, Senior Advisor, Business Finland
9.20 Co-innovation case: New modalities
Antti Haapalinna, Vice President, R&D, Rare Diseases, Biologics and New Modalities, Orion Oyj
9.35 Co-innovation case: ADELE
Aki Sinkkonen, PhD, PI, Adjunct Professor, Faculty of Biological and Environmental Sciences, University of Helsinki
9.50 Q&A
10.00 Presentation of co-creation projects
moderator: Hanna Rantala, Director, Business Finland
11.00 Networking and lunch
12.00 The event ends
BUSINESS FINLAND
Co-CREATION FUNDING
Research organizations
27.9.2019 Pekka Ollikainen
Co-Creation Develop a research idea, build on
cooperation
Research organizations and companies develop the research idea.
The funding will ensure the demand and suitability of a new research goal (problem to be solved) to businesses and construction of a new co-operation.
New business from research ideas (TUTLI)
Create new knowledge and business applications from research ideas
Business Finland –tutkimusrahoi
Research organisations develop new knowledge and solution models for new business purposes and and companies develop innovations for the global market.
Funding advances the use of research knowledge, increases the creation of new Finnish export products and strengthens networks in ecosystems.
Co-InnovationSearch for solutions with the help of research, cooperate and develop new export products
International and other special calls (ESA, ERDF, Eureka etc.) have their own specific criteria
Our funding services for research
Research organisations prepare an idea for business purposes.
Funding advances the commercialisation of research ideas.
4
Two paths to funding
If you have a new idea that could open up significant business opportunities for companies and you want to• Investigate and develop the idea
and its potential together with companies
• Create a consortium required for work and engage companies in development work
First contact the Research Funding Team of Business Finland for feedback on the idea. You may want to apply for Co-Creation funding.
If you already have the necessary companies committed to the project and development work already in the consortium, and you will be able to demonstrate the problem associated with the issue and the impact of its solution to the emergence of a significant business.
First contact the Research Funding Team of Business Finland for feedback and sparring. You may want to apply for Co-Innovation funding. 5
1 2
Co-Creation fundingFor whom?
For research organisationsaiming at to a Co-Innovation project to be completed in close co-operation with companies
For what purpose?
Research organisations and companies jointly develop a research idea. The goal is to create a Co-Innovation project (joint action) among companies and researchers.
Funding ensures the need for the research goal and the solution and its suitability for business use. It also helps build a network for a possible Co-Innovation project.
Not necessary for all: Formed consortiums can advance directly to the Co-Innovation funding phase.
6
Co-Creation funding
How does it work?
Funding covers 60% of the project’s total expenses
The maximum size of the project is 100 000 euros.
Project duration 4–6 months
Fixed overhead percentage 20% and coefficient for indirect employee costs 50%
Equipment costs are not accepted
No application period
Final report, no audit7
Applying for Co-Creation fundingContact the Research Funding Team of Business Finland and prepare in advance to tell your idea:
NEED
What is the problem solved by the research idea?Has the matter been discussed with companies (which companies)? Are companies willing to participate in development work?Is Co-Innovation Consortium required to stage the company already ready?
BENEFIT
If your research succeeds, what kind of business opportunities will be created?What is the preliminary estimate based on?What kind of businesses could interest the subject?
SOLUTION
How is the solution sought (solution model)?
COMPETITION
Has the subject been studied elsewhere, and where? What's new here? Has this been previously funded
8
Co-Creation funding
What are the criteria for the funding?
The novelty value and business potential of the idea
The quality of the plan to determine the relevance of the idea and demand (problem-solution fit)
The quality of the plan to create cooperation with companies and the R&D consortium
Including Business Finland’s strategic and programmes´ themes in the plan will positively influence the evaluation process. 9
What kind of work is funded in Co-Creation project?
The demonstration the relevance of the research idea and the relevant demand for the subject, to further develop and improve the idea
The creation of an interaction model and a business network as well as an international network needed in research and innovation development (freedom of action in the area, IPR, ...)
Other matters related to the feasibility of the idea of work
The application defines the preliminary problem to be solved and its solution model. This idea must be widely utilized.
The project deepens understanding of the importance of the problem and the solution model and whether it is solving the right problem.
10
Contact our Research Funding Team!
11
Mika Lautanala
+358 50 557 7838
Digitalisation
Kimmo Ahola
+358 50 557 7756
Consumer Business
Kenneth Nyholm+358 50 395 6028
Bio and CircularEconomySisko Sipilä
+358 50 557 7845
Cleantech
Kari Koskela
+358 50 439 5736
Health and Wellbeing
Pekka Ollikainen
+358 50 557 7758
Emails:
9-2019-vpo
You may also contact to your named contact person at Business Finland
Co-innovation case: New modalities
Antti Haapalinna, Professor, Ph.D, eMBA
Vice President, R&D
Global Head, Therapy Area Rare Diseases,
Biologics, Biomarkers and New Modalities
Function
Orion Corporation, ORION PHARMA
Public-Private Partnerships in Life Sciences – Co-creation,
Co-innovation and how to get Started?
Helsinki 27.9.2019
World has become and is becoming more complex ...
Regulatory
• Price regulations increasing
• Reimbursement requirements increasing
• Scrutiny on drug efficacy and safety intensifying
• Time span of regulatory processes extending
Technology
• R&D productivity more challenging
• Role of biologicals has increased
• Alternative technologies emerging
• Industry consolidation intensifying
• Digitalization /E-commerce opportunities
broadening
Consumer
• Population aging
• Health awareness intensifying
• Demand for personalised therapy increasing
• Service concepts broadening
• New distribution channels emerging
• Private spend on medicines increasing
Open
Science
RECENT
THEMES
Disruptive
innovations
Social
media
Big data Companion
diagnostics
Open
innovation
Biobanks
Advanced
therapies
Customer/
patients on
focus
Socio-economic
• Economic downturn still influencing
• Role of innovations as growth driver increasing
• Number of generic launches increasing
• Growth in emerging markets increasing
• Competition intensifying
• Numerous market specific payer actions
emerging
© Orion R&D
Why ? What ? How?
Operational environment is dramatically changing. New technologies are emerging,
attrition is high because lack of efficacy, price and reimbursement regulations increasing,
large diseases will be fragmented, patient stratification important. More and more target
proteins emerging that are not amenable for small molecules. Need for real world data
for clinical benefit.
We need to build competencies for new treatment modalities in addition to small
molecules. Rare monogenic diseases provide a way for less risky, systematic target
(protein or gene) selection for application of new technologies. As well as reveal
biochemical pathways that possibly results in treatment of a more common condition.
Start to broaden our competencies for biologics (therapeutic proteins) with systematic
piloting of other new technologies. Start with Finnish genetic Rare diseases, providing
excellent genetic and clinical basic research and network.
Antti Haapalinna Orion Oyj
More and more target proteins emerging that are not amenable for small
molecules. When having competencies in biologics, there is an opportunity to
combine mAbs with small molecule competencies regarding antibody drug conjugates (ADC)
ADC (antibody drug conjugate)
Darolutamide
C19H19ClN6O2
399 g/mol
IgG2a Antibody
C6440H9962N1704O2014S56
146,277 g/mol
Monoclonal
Antibody
(mAb)
Antti Haapalinna Orion Pharma
• Small molecules
• Biologics (mAb, affinity proteins)
• Therapeutic peptides
• Therapeutic nucleic acids
• Gene therapy…
● There are between 6000 and 8000 rare diseases.
30 million individuals each in EU and USA have
Rare (orphan) diseases
● 75 % of rare diseases affect children
● 80 % of rare diseases have identified genetic
origin which means that reason for condition
is known.
● Many rare diseases remain without effective
treatments
● The genetic origin is identified for all
of the 36 rare diseases
● In many of these diseases a single point
mutation leads to a single amino acid
substitution and a defective protein
Finnish Disease HeritageRare Diseases
Rare genetic diseases may provide a way for less
risky systematic target selection for application of
new technologies than common disease where
ultimate reason of the disease is not known
16
Genetic
defect
Dysfunctional
proteinDisease and
symptoms
Pathological
process
• Disease Biology understanding
• Patient stratification
• Meaningful clinical end points
• New technology /real world
Data / evidence
17
From one ecosystem to multiple parallel ecosystems
Business Finland grant,
positive decision obtained
at 28th August 2018 for
New Modalities
Ecosystem for developing
capabilities in Rare
Diseases, Biologics and
New Treatment Modalities https://www.businessfinland.fi/en/w
hats-new/news/2018/creation-of-
novel-medicines-and-better-
patient-care-for-the-future-in-an-
ecosystem/
Antti Haapalinna Orion Pharma
● 20 March 2018 First visit to Business Finland
– BF: ”Would Orion build an ecosystem” ?
● 21st March – 28 April; first contacts, meetings and writing plans with the ecosystem partners
● 30 April 2018 all applications filed at the same time with Orion
● 28 August BF BOD approval for the Ecosystem
– Starting of actual work
● Ecosystem contract ready and signed in spring 2019
“Where there's a will there's a way”
“The aim of this New Modalities Ecosystem is enable improved understanding of disease pathology related to
the symptoms and disease progression and better treatments by applying large molecular drugs and diagnostic
tools as well as digital wearable patient tools for disease symptom recording. This Ecosystem combines in a
unique way high-level academic research with industrial drug research and development. The Ecosystem
participants include in addition to Orion, University of Turku, University of Helsinki, University of Eastern
Finland, Folkhälsan as well as the companies PerkinElmer, Syrinx Bioanalytics, AdmeScope, Petsofi, Forendo
Pharma.”
Antti Haapalinna Orion Pharma
Knowledge and technology ecosystem
A bridge between technology and biology
Antti Haapalinna Orion Pharma
Disease Biology
understanding New treatments
technologies
understanding
Building an ecosystem for developing capabilities in
Rare Diseases, Biologics and New Treatment Modalities
Syrinx Bioanalytics
Biomarkers
Admescope
Bioanalytics
DMPK
Ecosystem for developing capabilities in
Rare Diseases
• Increased knowledge on disease-specific
as well as common biochemical pathways
• Novel drug targets
• Diagnostic tools and biomarkers for
patient stratifications and clinical trials
• Wearable patient tools; sensors for
myoclonus detection and for patient on-
line reporting of their condition
Disease Biology understanding, patient stratification,
Meaningful clinical end points, real world evidenceBiomolecule and technology knowledge and tools
Antti Haapalinna Orion Pharma
Progressive Myoclonus
Epilepsy, EPM1
Common features• Juvenile onset of disease
• Neurodegeneration with same brain areas
• Similar kind symptoms; severe disabilities
in motor coordination
21
Understanding and
measurement of symptoms
• Meaningful clinical end
points
• New technology /real
world Data / evidence
Common and specific target proteins in
movement disorder syndromes
and biochemical pathways possibly resulting
in treatments also of more common
conditions (e.g. Parkinson’s disease)
Mitochondrial Recessive
Ataxia Syndrome, MIRAS
Anu Wartiovaara MD, PhD,
Academy ProfessorReetta Kälviäinen MD, PhD,
Professor of Neurology
Anna-Elina Lehesjoki
MD, PhD, Professor of
Medical Genetics
Disease Biology
understanding and
measurement
• Diagnostic tools and
biomarkers for patient
selection and
following efficacy in
clinical trials
Antti Haapalinna Orion Pharma
Target confidence, patient stratification
Meaningful clinical end pointsMolecule and technology confidence
A bridge between technology and biology
Antti Haapalinna Orion Pharma
Knowledge and technology ecosystem
Modality agnostic approach
select the most appropriate
drug targets to provide best
treatment for patients without
limitations to certain treatment
modalities
Building knowledge ecosystem to
provide
Biologics (mAb, affinity
proteins)
Therapeutic peptides
Therapeutic nucleic acids
Targeted Delivery of Oligonucleotide-based Drugs
Bioorganic group, Professor Pasi Virta/
Urpo Lamminmäki /Recombinant Protein Platforms for Drug Lead Discovery by the antibody
engineering group
Companies for technology ecosystem:
Technology ecosystem
Antti Haapalinna Orion Pharma
SYRINX Bioanalytics
● Pharmacokinetic assays for next generation oligonucleotides and targeted delivery
● New analytical challenges for immunogenicity testing
● Pharmacodynamic biomarker assays related to the use of oligonucleotide therapies
Admescope
● Analytical methodology for therapeutic nucleotides and peptides for distribution, pharmacokinetics, metabolomic faith, cell entrance and
biological effects and efficiency
● Ligand binding methods for immunochemical and biological properties of New modalities
● Drug-drug-interactions of New modalities
Forendo Pharma
● core competence in tissue-specific regulation of sex hormone effects.
Knowledge and technology ecosystem
Disease Biology understanding, patient stratification
Meaningful clinical end points, new technology /real world
data/ evidence
Biomolecule and technology confidence
A bridge between technology and biology • Increased knowledge on disease-specific as well
as common biochemical pathways
• Diagnostic tools and biomarkers for patient
stratifications and clinical trials
• Wearable patient tools; sensors for myoclonus
detection and for patient on-line reporting of their
condition Modality agnostic approach
select the most appropriate drug targets to provide best
treatment for patients without limitations to certain
treatment modalities
Building knowledge and technology ecosystem to provide
Biologics (mAb, affinity proteins)
Therapeutic peptides
Therapeutic nucleic acids
Antti Haapalinna Orion Pharma
Business Finland
public private funding
(for 3 years) received
28.8.2018
Ecosystem agreement
• Common frame for collaboration
• To protect background data
• Enabling publishing and data protection
Agreements between parties for IPR sensitive issues
Joint yearly event for all participants at Orion training
center in mid June.
Antti Haapalinna Orion Pharma
26
It is important to industry to
understand clinical practice
New medicines to
patients / clinical trials
Offering academia opportunities e.g. access to new
molecules => expand knowledge of MoA / disease
mechanisms
Basic research findings
New technologies
Medical
knowledge of
TA & MoA
Samples:
Disease -
Biomarker
discovery
Adverse effect
monitoring
New treatments
Devices
Diagnostics
Enabler & coordinator
Help to identify key priorities
Provide project management enablers
Regulatory knowledge
ACADEMIA COMPANIES(large and SMEs)
HEALTHCARE
PROFESSIONALS
Samples
Mutual desire: Provide patients with access to new
more effective and safe treatments and care (from Open Science to Open innovation)
© Orion R&D
Press releases:
https://www.businessfinland.fi/ajankohtaista/uutiset/2018/tulevaisuuden-laake--ja-hoitomuotoja-kehitetaan-ekosysteemissa/
https://www.orion.fi/konserni/media/lehdistotiedotteet/2018/tulevaisuuden-laake--ja-hoitomuotoja-ekosysteemissa/
https://www.orion.fi/en/Orion-group/media/press-releases/2018/creation-of-novel-medicines-and-better-patient-care-for-the-future-in-an-ecosystem/
http://www.globenewswire.com/news-release/2018/09/17/1571506/0/en/Creation-of-novel-medicines-and-better-patient-care-for-the-future-in-an-ecosystem.html
https://www.helsinki.fi/fi/uutiset/terveys/helsingin-yliopisto-ja-orion-oyj-yhdistavat-voimansa-mitokondriotautien-ja-etenevan-myoklonusepilepsian-hoitotutkimuksessa
https://www.utu.fi/fi/Ajankohtaista/mediatiedotteet/Sivut/Turun-yliopisto-kehittaa-tulevaisuuden-laake-ja-hoitomuotoja-osana-laajempaa-ekosysteemia.aspx
Articles:
http://edition.pagesuite-professional.co.uk/html5/reader/production/default.aspx?pnum=156&edid=73e202a8-1e25-4d2e-afc3-1cd95c26e5ae&isshared=true
http://edition.pagesuite-professional.co.uk/html5/reader/production/default.aspx?pnum=158&edid=5ffe2a2a-df10-462e-a709-5910f039b796&isshared=true
Collaboration on education:
https://www.utu.fi/fi/ajankohtaista/uutinen/turun-yliopisto-ja-orion-oyj-ryhtyvat-kouluttamaan-yhteistyossa
Q&A?
Antti Haapalinna Orion Pharma
Bio- ja ympäristötieteellinen tiedekunta
Aki Sinkkonen* and the ADELE team* ** ***
*University of Helsinki, Ecology and Environment Research Program **Tampere University of Technology, School of Architecture
***University of Tampere, Faculty of Medicine and Life Sciences
CASE ADELE
18/10/2019Helsinki 2019 28
Bio- ja ympäristötieteellinen tiedekunta
FROM INFECTIOUS DISEASES TO IMMUNE-MEDIATED DISEASES
18/10/2019Helsinki 2019 29
Identify the problem
Bio- ja ympäristötieteellinen tiedekunta
IMMUNE-MEDIATED DISEASES
• If harmless environmentalmicrobiota is rare
→ immune system finds alternative targets
- Own cells, e.g. type 1 diabetes
- Gut microbes, e.g. irritable bowel syndrome
- Pollen or food particlesallergies
20 % of people affected in welfare states
18/10/2019 30
Bio- ja ympäristötieteellinen tiedekunta
SOLUTION
• Diverse nature-derived microbiota
18/10/2019Presentation Name / Firstname Lastname 31
Bio- ja ympäristötieteellinen tiedekunta
BIODIVERSITY PRODUCTS IN 2020’S
18/10/2019 32Helsinki 2019 – [email protected]
Bio- ja ympäristötieteellinen tiedekunta
WHO IS INTERESTED IN THIS IDEA?
33
STEP 1:
FIND THE RIGHT PARTNERS IN RESEARCHER COMMUNITY
STEP 2:
FIND THE RIGHT COLLABORATORS FROM ENTERPRISES
TENS (HUNDREDS) OF CALLS
30 VISITS
20 FAILS
WE HAVE A CONSORTIUM
EMAIL = FAIL
Bio- ja ympäristötieteellinen tiedekunta
REASONS FOR FAIL?
TOO HIGH PRICE TAG
TOO FAR FROM CURRENT RESEARCH AND DEVELOPMENT
TOO EAGER TO JOIN = NO UNDERSTANDING OF RESEARCH
CHANGES IN OWNERSHIP
SUDDEN DROP IN REVENUE
18/10/2019Presentation Name / Firstname Lastname 34
Bio- ja ympäristötieteellinen tiedekunta
REASONS FOR SUCCESS?
• High quality consortium
• Karolinska Institutet
• Technische Universität Darmstadt
• Opponent (Technische UniversitätGraz) of a Ph. D. defense is nowinvolved
18/10/2019Presentation Name / Firstname Lastname 35
Bio- ja ympäristötieteellinen tiedekunta
REASONS FOR SUCCESS?
• CLEAR UNDERSTANDING OF BUSINESS OPPORTUNITY
• WE HELPED IN WRITING THE APPLICATION
18/10/2019Presentation Name / Firstname Lastname 36
Bio- ja ympäristötieteellinen tiedekunta
REASONS FOR SUCCESS?
• KEY PERSONNEL KNOWS THE SCIENCE
• WE PROPOSED HOW TO INTEGRATE US WITH THEIR CURRENT R&D
18/10/2019Presentation Name / Firstname Lastname 37
Bio- ja ympäristötieteellinen tiedekunta
REASONS FOR SUCCESS?
• RIGHT BACKGROUND OF THE COMPANY
• GOOD ECONOMY
• NOT TOO BIG FAST DECISIONS
• KEY PERSONNEL KNOWS FINNISH UNIVERSITY SYSTEM
18/10/2019Presentation Name / Firstname Lastname 38
Bio- ja ympäristötieteellinen tiedekunta
REASONS FOR SUCCESS?
• ATTITUDE
• THOSE WHO TAKE R&D RISKS ARE LIKELY TO SAY YES
• DIPP
18/10/2019Presentation Name / Firstname Lastname 39
• Orion oyj
• Delipap oy
Bio- ja ympäristötieteellinen tiedekunta
REASONS FOR SUCCESS?
• PATENTING
• FIGHT AGAINST DEVIL’S ADVOCATES
• DO IT BEFORE PUBLISHING
• AS TIME CONSUMING AS FINDING PARTNERS
18/10/2019Presentation Name / Firstname Lastname 40
• Orion oyj
• Delipap oy
Bio- ja ympäristötieteellinen tiedekunta
SHOW UNPUBLIHSED RESULTS
Avoid jargon
20/3/[email protected] 41
0
1
2
3
4
5
6
Interventio Kaupunki Luonto
Ennen Jälkeen
0
2
4
6
8
10
12
14
Interventio Kaupunki Luonto
Ennen Jälkeen
0
1
2
3
4
5
Interventio Kaupunki Luonto
Ennen Jälkeen
Special thanks to Heikki Hyöty’s and Juho Rajaniemi’s groups at Tampere University
www.helsinki.fi/nature-based-solutions
Right clothes and smile
Presentation of co-creation projects
Questions:1. What problem are you trying to solve?2. What is your vision/solution and what you need to achieve it?3. What is the ideal consortium for the purposes of the research (co-innovation project) - what kind of partners you are looking for?
1. Vesa Linnamo, University of Jyväskylä: SilverEconomy
2. Jarmo Perttunen, TAMK: Haavan lämpökuvaus älypuhelimella
3. Arto Pesola / Xamk Active Life Lab: CogTail
4. Tomasz Sokalski, Åbo Akademi University: Intelligent Artificial Nose and Tongue Technology – ANTTI
5. Hanna-Leena Alakomi, VTT: Added value for Finnish food export products, innovative logistics
Outi [email protected]+358 50 339 2542
http://www.businessfinland.fi/personalizedhealth